NASDAQ:JANX Janux Therapeutics (JANX) Stock Price, News & Analysis → Breaking - The US Gov. Seized CITGO (From Augury Research) (Ad) Free JANX Stock Alerts $44.16 +1.57 (+3.69%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$42.00▼$44.6650-Day Range$35.12▼$64.7852-Week Range$5.65▼$65.60Volume401,508 shsAverage Volume807,466 shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$66.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Janux Therapeutics alerts: Email Address Janux Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside50.1% Upside$66.29 Price TargetShort InterestHealthy8.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 15 Articles This WeekInsider TradingSelling Shares$164.25 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.34) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector252nd out of 905 stocksPharmaceutical Preparations Industry113th out of 430 stocks 4.4 Analyst's Opinion Consensus RatingJanux Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageJanux Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Janux Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted8.54% of the float of Janux Therapeutics has been sold short.Short Interest Ratio / Days to CoverJanux Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Janux Therapeutics has recently decreased by 12.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJanux Therapeutics does not currently pay a dividend.Dividend GrowthJanux Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JANX. Previous Next 1.8 News and Social Media Coverage News SentimentJanux Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Janux Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 14 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,250,000.00 in company stock.Percentage Held by Insiders35.40% of the stock of Janux Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Janux Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.34) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Janux Therapeutics is -36.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Janux Therapeutics is -36.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJanux Therapeutics has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Janux Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Augury ResearchBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is currently auctioning off CITGO (the winning bid will be announced on July 22nd).Get all the details here. About Janux Therapeutics Stock (NASDAQ:JANX)Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Read More JANX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JANX Stock News HeadlinesJune 6 at 6:54 AM | insidertrades.comJanux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Sells $37,081,025.25 in StockJune 7 at 4:14 AM | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) CFO Tighe Reardon Sells 822,721 SharesJune 7 at 4:14 AM | americanbankingnews.comVentures Xi L.P. Avalon Sells 677,279 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) StockJune 6 at 8:24 AM | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Shares Down 7% June 6 at 6:56 AM | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Director Jay Lichter Sells 1,500,000 Shares of StockJune 4 at 1:12 AM | americanbankingnews.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Moderate Buy" by AnalystsJune 2, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Trading Up 5%May 31, 2024 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Coverage Initiated by Analysts at ScotiabankMay 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)May 13, 2024 | markets.businessinsider.comAnalyst Ratings For Janux TherapeuticsMay 8, 2024 | benzinga.comJanux Therapeutics Options Trading: A Deep Dive into Market SentimentMay 8, 2024 | finance.yahoo.comJanux Therapeutics Reports Narrower Q1 Loss, Misses Revenue EstimatesMay 7, 2024 | businesswire.comJanux Therapeutics Reports First Quarter 2024 Financial Results and Business HighlightsMay 2, 2024 | msn.comJanux Therapeutics gains amid renewed takeover speculationApril 30, 2024 | finance.yahoo.comHere's What Could Help Janux Therapeutics (JANX) Maintain Its Recent Price StrengthApril 17, 2024 | investorplace.comTake the Money and Run: 3 Overbought Stocks to Sell ASAPApril 17, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - JANXApril 16, 2024 | msn.comJonesTrading Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationApril 16, 2024 | msn.comJanux a new buy at Jones on lead assets for solid tumorsApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?April 16, 2024 | benzinga.comA Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 AnalystsApril 12, 2024 | fool.comWhy Janux Therapeutics Stock Is Crushing It This WeekApril 11, 2024 | theglobeandmail.comStocks See Continued Pressure as Bond Yields ClimbApril 11, 2024 | benzinga.comWhy Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?April 11, 2024 | finance.yahoo.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsSee More Headlines Receive JANX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/07/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:JANX CUSIPN/A CIK1817713 Webwww.januxrx.com Phone858-751-4493FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$66.29 High Stock Price Target$100.00 Low Stock Price Target$47.00 Potential Upside/Downside+53.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-58,290,000.00 Net Margins-762.92% Pretax Margin-762.92% Return on Equity-13.49% Return on Assets-12.37% Debt Debt-to-Equity RatioN/A Current Ratio62.09 Quick Ratio62.09 Sales & Book Value Annual Sales$8.08 million Price / Sales277.35 Cash FlowN/A Price / Cash FlowN/A Book Value$7.46 per share Price / Book5.79Miscellaneous Outstanding Shares51,850,000Free Float33,496,000Market Cap$2.24 billion OptionableOptionable Beta3.71 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. David Alan Campbell Ph.D. (Age 64)President, CEO & Director Comp: $1.04MMr. Charles M. Winter (Age 55)Chief Technical Officer Comp: $590.4kMr. Byron Robinson J.D. (Age 59)Ph.D., Chief Strategy Officer Comp: $723kMr. Tighe M. Reardon C.F.A. (Age 48)CPA, Acting Chief Financial Officer Dr. Tommy Diraimondo Ph.D. (Age 38)Chief Scientific Officer Mr. James PenningtonGeneral CounselMs. Brenda Van VreeswykHead of Human ResourcesMr. Andy Hollman Meyer (Age 40)Chief Business Officer More ExecutivesKey CompetitorsDICE TherapeuticsNASDAQ:DICEPandion TherapeuticsNASDAQ:PANDPraxis Precision MedicinesNASDAQ:PRAXScholar RockNASDAQ:SRRKALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsVentures Xi L.P. AvalonSold 677,279 sharesTotal: $37.08 M ($54.75/share)Jay LichterSold 1,500,000 sharesTotal: $82.13 M ($54.75/share)Tighe ReardonSold 822,721 sharesTotal: $45.04 M ($54.75/share)Virtu Financial LLCBought 16,183 shares on 5/20/2024Ownership: 0.031%Artal Group S.A.Bought 50,000 shares on 5/17/2024Ownership: 0.096%View All Insider TransactionsView All Institutional Transactions JANX Stock Analysis - Frequently Asked Questions Should I buy or sell Janux Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Janux Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JANX shares. View JANX analyst ratings or view top-rated stocks. What is Janux Therapeutics' stock price target for 2024? 8 brokerages have issued 1-year price targets for Janux Therapeutics' shares. Their JANX share price targets range from $47.00 to $100.00. On average, they expect the company's stock price to reach $66.29 in the next twelve months. This suggests a possible upside of 50.1% from the stock's current price. View analysts price targets for JANX or view top-rated stocks among Wall Street analysts. How have JANX shares performed in 2024? Janux Therapeutics' stock was trading at $10.73 at the beginning of 2024. Since then, JANX shares have increased by 311.6% and is now trading at $44.16. View the best growth stocks for 2024 here. When is Janux Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our JANX earnings forecast. How were Janux Therapeutics' earnings last quarter? Janux Therapeutics, Inc. (NASDAQ:JANX) announced its earnings results on Tuesday, May, 7th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.05. The business had revenue of $1.25 million for the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative trailing twelve-month return on equity of 13.49% and a negative net margin of 762.92%. What ETFs hold Janux Therapeutics' stock? ETFs with the largest weight of Janux Therapeutics (NASDAQ:JANX) stock in their portfolio include Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).Fidelity Disruptive Medicine ETF (FMED). When did Janux Therapeutics IPO? Janux Therapeutics (JANX) raised $152 million in an IPO on Friday, June 11th 2021. The company issued 9,500,000 shares at $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager. Who are Janux Therapeutics' major shareholders? Janux Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BVF Inc. IL (5.63%), Janus Henderson Group PLC (3.79%), Vanguard Group Inc. (2.62%), Lord Abbett & CO. LLC (1.05%), Altitude Crest Partners Inc. (0.37%) and StemPoint Capital LP (0.23%). Insiders that own company stock include Corp Bregua, Jay Lichter, Orbimed Advisors Llc, Ra Capital Management, LP, Tighe Reardon and Ventures Xi LP Avalon. View institutional ownership trends. How do I buy shares of Janux Therapeutics? Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JANX) was last updated on 6/7/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.